美通社

2024-09-25 06:01

EADV Congress 2024: Semaglutide improves outcomes for obese patients with common skin condition, new study shows

A pioneering study, presented today at the EADV Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic skin condition, in people with obesity.

AMSTERDAM, Sept. 25, 2024 /PRNewswire/ -- This is the first study to explore the use of semaglutide for HS, marking a critical milestone in the search for effective treatments for this painful and debilitating condition.

HS is currently estimated to affect approximately 1 in 100 people, with obesity being a significant risk factor. The condition is characterised by painful abscesses and scarring, which can severely impact patients' quality of life. Despite advancements in managing HS, effective treatments remain limited and can cause serious side effects, highlighting a need for alternative and better-tolerated treatment options.

The study, which examined data from June 2020 to March 2023, assessed health outcomes for 30 obese patients with varying stages of HS. Patients received semaglutide – a glucagon-like peptide (GLP)-1RA – at a once-weekly mean dose of 0.8mg for an average of 8.2 months.

The results showed marked improvements in patient outcomes across several key measures.

Patients experienced fewer HS flare-ups, with the frequency of these episodes reducing from an average of once every 8.5 weeks to once every 12 weeks. Quality of life also improved significantly, reflected in a reduction of the Dermatology Life Quality Index (DQLI) score from an average of 13/30 to 9/30.

The average BMI of patients decreased from 43.1 to 41.5 and their mean weight dropped significantly from 117.7kg to 111.6kg, with one-third of patients losing 10kg or more during the treatment period.

Further positive changes were observed in the biochemical markers assessed. HbA1c levels decreased from 39.3 to 36.6, indicating better glycaemic control, while average CRP levels fell from 7.8 to 6.9, signifying reduced inflammation.

Dr Daniel Lyons, lead researcher, explains, "Our findings suggest that semaglutide, even at modest doses, can offer substantial benefits in managing HS. While the drug's role in promoting weight loss is well-established, what's particularly exciting is its potential to also reduce the frequency of HS flare-ups, contributing to the notable improvements observed in patients' quality of life."   

Dr Lyons adds, "The results are highly encouraging and could represent a major breakthrough in HS treatment. To build on this progress, larger randomised controlled trials are necessary to validate these findings."

 

 

source: EADV

【你點睇?】美歐官員今周商俄烏戰爭問題,你認為俄烏戰爭是否正加快步向結束?► 立即投票

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
3
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
4
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
5
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
6
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
7
一本萬利 | 2025年的五個「勿」(有片)
8
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
9
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
10
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
11
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
12
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
13
【FOCUS】侵侵就職倒數一周,美元及油價劇本臨揭盅
14
洪灝專訪 | 淘寶衝擊巨大,港樓價未反映大周期拐點(有片)
15
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
16
習近平應約與特朗普通電話,特:冀盡快與習見面
17
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
18
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
19
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
20
雷賢達觀點 | 香港篇:恒指年波幅料六千點,港須全面融入大灣區
21
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
22
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
23
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
24
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
25
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
26
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
27
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
28
特朗普就職 | 特朗普上台後行動列表
29
馬斯克明拆特朗普台,指其星際之門計劃「假大空」
30
【FOCUS】侵侵呼籲全球「降息」,日銀祭18年最激進加息
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

流感高峰期

山今養生智慧

輕鬆護老